首页> 美国卫生研究院文献>Respiratory Research >Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

【2h】

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

机译：单吸入器外列三重治疗的疗效和安全性与吸入皮质类固醇加上东亚患者的长效β2激动剂：Triversyti随机对照试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The online version contains supplementary material available at 10.1186/s12931-021-01683-2.

机译：在线版包含10.1186 / s12931-021-01683-2可用的补充材料。

著录项

期刊名称 Respiratory Research
作者
Jinping Zheng; Simonetta Baldi; Li Zhao; Huiping Li; Kwan-Ho Lee; Dave Singh; Alberto Papi; Frédérique Grapin; Alessandro Guasconi; George Georges;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 12
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词
Triple inhalation therapy; Chronic obstructive pulmonary disease; Chronic bronchitis; Airway obstruction; Extrafine;

机译：三重吸入治疗;慢性阻塞性肺病;慢性支气管炎;气道阻塞;外列;

相似文献

外文文献
中文文献

1. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta(2)-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial [J] . Singh Dave, Papi Alberto, Corradi Massimo, The Lancet . 2016,第10048期

机译：单吸入器三联疗法与吸入性糖皮质激素加长效β（2）激动剂治疗慢性阻塞性肺疾病（TRILOGY）：双盲，平行组，随机对照试验
2. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial [J] . Bleecker Eugene R., FitzGerald J. Mark, Chanez Pascal, The Lancet . 2016,第10056期

机译：苯那珠单抗对重症哮喘患者的高剂量吸入性糖皮质激素和长效β2-激动剂（SIROCCO）无法控制的有效性和安全性：一项随机，多中心，安慰剂对照的3期试验
3. Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting beta(2)-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial [J] . Devillier Philippe, Humbert Marc, Boye Alain, Respiratory medicine . 2018,第期

机译：曾经每日氟替卡塞呋喃/维替醇（FF / VI）的疗效和安全性与两次吸入皮质类固醇/长效β（2）患者的患者（ICS / LABA）在不受控制的哮喘：开放标签，随机，受控试验
4. Addition of leukotriene receptor antagonists versus long acting beta agonists to inhaled corticosteroid therapy for asthma treatment in older adults: A retrospective data analysis of effectiveness, safety and cost. [D] . Altawalbeh, Shoroq Mahmoud. 2015

机译：在吸入性糖皮质激素治疗中，将白三烯受体拮抗剂与长效β激动剂相比，用于老年人的哮喘治疗：有效性，安全性和成本的回顾性数据分析。
5. Efficacy and safety of single-inhaler triple therapy of glycopyrronium formoterol and fluticasone in patients with COPD: a double-blind randomised controlled trial [O] . Sundeep Salvi, Akash Balki, Srikanth Krishnamurthy, 2021

机译：COPD患者糖酮Formoterol和Fluticasone的单吸收三重治疗的功效和安全性：双盲随机对照试验
6. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial [O] . Jinping Zheng, Simonetta Baldi, Li Zhao, 2021

机译：单吸入器外列三重治疗的疗效和安全性与吸入皮质类固醇加上东亚患者的长效β2激动剂：Triversyti随机对照试验

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅